Supporting global efforts in combating the COVID-19 pandemic
COVID-19 is having a major impact on society in how people live their lives, on public health and industry, as lock-down restrictions are put in place to control the spread of the virus. This is impacting economies worldwide.
Testing has been a core strategy in many countries, not only to diagnose but to screen and monitor disease spread, with regular testing becoming part of our everyday lives as we begin to get back to more normal ways of life1.
Around 1 in 3 people with COVID-19 do not show any symptoms but can still infect others. Rapid lateral flow tests help to find these cases.
Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer® platform to develop diagnostics for COVID-19 antigen testing.
Avacta has generated a large number of Affimer® binders to the SARS-CoV-2 virus spike protein including Affimer® pairs for sandwich assays and Affimer® inhibitors of the spike-ACE2 interaction.
Avacta is developing a number of SARS-CoV-2 tests:
- The AffiDX® SARS-CoV-2 lateral flow antigen test intended for screening of populations to diagnose the COVID-19 coronavirus infection.
- A high throughput laboratory test for the infection, to run on the installed base of mass spectrometers in hospitals and laboratories.
- An ELISA laboratory test to support global research efforts into the coronavirus that causes COVID-19.
Avacta’s COVID-19 programmes are rapidly evolving. View the latest news updates.
Image for illustrative purposes only.